Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHE NASDAQ:GRCE NASDAQ:IMRN NASDAQ:LSTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.21-98.0%$4.21$4.14▼$350.00$36.44M0.3100,728 shs55,562 shsGRCEGrace Therapeutics$2.20-4.3%$2.93$1.79▼$5.18$35.59M0.37262,082 shs406,734 shsIMRNImmuron$1.19-4.0%$0.98$0.68▼$2.39$10.13M1.11666,576 shs24,793 shsLSTALisata Therapeutics$3.56+2.3%$3.62$1.81▼$5.07$31.69M0.81219,056 shs56,329 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics-0.96%+4.58%-14.91%+14.17%-12.55%GRCEGrace Therapeutics-0.43%-4.37%-1.29%-45.24%-19.30%IMRNImmuron+4.27%-3.94%+52.31%+49.69%-31.03%LSTALisata Therapeutics-3.60%+3.26%+6.75%-30.82%+41.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.21-98.0%$4.21$4.14▼$350.00$36.44M0.3100,728 shs55,562 shsGRCEGrace Therapeutics$2.20-4.3%$2.93$1.79▼$5.18$35.59M0.37262,082 shs406,734 shsIMRNImmuron$1.19-4.0%$0.98$0.68▼$2.39$10.13M1.11666,576 shs24,793 shsLSTALisata Therapeutics$3.56+2.3%$3.62$1.81▼$5.07$31.69M0.81219,056 shs56,329 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics-0.96%+4.58%-14.91%+14.17%-12.55%GRCEGrace Therapeutics-0.43%-4.37%-1.29%-45.24%-19.30%IMRNImmuron+4.27%-3.94%+52.31%+49.69%-31.03%LSTALisata Therapeutics-3.60%+3.26%+6.75%-30.82%+41.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHEAlterity Therapeutics 2.00HoldN/AN/AGRCEGrace Therapeutics 2.00Hold$6.00172.73% UpsideIMRNImmuron 1.00SellN/AN/ALSTALisata Therapeutics 1.67Reduce$15.00321.35% UpsideCurrent Analyst Ratings BreakdownLatest IMRN, ATHE, GRCE, and LSTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026LSTALisata Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/15/2026LSTALisata Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral4/24/2026GRCEGrace Therapeutics Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.004/24/2026GRCEGrace Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $8.004/21/2026GRCEGrace Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026LSTALisata Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ATHEAlterity Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026IMRNImmuron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHEAlterity TherapeuticsN/AN/AN/AN/A$3.10 per shareN/AGRCEGrace TherapeuticsN/AN/AN/AN/A$4.86 per shareN/AIMRNImmuron$4.72M2.06N/AN/A$0.78 per share1.53LSTALisata Therapeutics$170K190.77N/AN/A$1.66 per share2.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHEAlterity Therapeutics-$7.87MN/AN/AN/AN/AN/AN/AN/A8/28/2026 (Estimated)GRCEGrace Therapeutics-$9.57M-$0.40N/AN/AN/AN/A-15.58%-14.51%6/22/2026 (Estimated)IMRNImmuron-$3.38MN/AN/AN/AN/AN/AN/AN/A8/28/2026 (Estimated)LSTALisata Therapeutics-$16.59M-$1.86N/AN/AN/AN/A-103.54%-83.08%8/6/2026 (Estimated)Latest IMRN, ATHE, GRCE, and LSTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/22/2026Q4 2026GRCEGrace Therapeutics-$0.24N/AN/AN/A$0.90 millionN/A5/11/2026Q1 2026LSTALisata TherapeuticsN/A-$0.50N/A-$0.50N/AN/A4/30/2026Q1 2026IMRNImmuronN/A-$0.0950N/A-$0.0950N/A$1.40 million3/12/2026Q4 2025LSTALisata Therapeutics-$0.74-$0.33+$0.41-$0.33N/A$0.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATHEAlterity TherapeuticsN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/AIMRNImmuronN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHEAlterity TherapeuticsN/A21.97N/AGRCEGrace TherapeuticsN/A14.9614.96IMRNImmuronN/A8.046.83LSTALisata TherapeuticsN/A4.234.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHEAlterity Therapeutics2.14%GRCEGrace Therapeutics6.08%IMRNImmuron0.12%LSTALisata Therapeutics8.94%Insider OwnershipCompanyInsider OwnershipATHEAlterity Therapeutics38.80%GRCEGrace Therapeutics11.10%IMRNImmuron7.01%LSTALisata Therapeutics9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableGRCEGrace TherapeuticsN/A15.47 million13.76 millionN/AIMRNImmuronN/A8.17 million7.59 millionNot OptionableLSTALisata Therapeutics309.11 million8.23 millionNot OptionableIMRN, ATHE, GRCE, and LSTA HeadlinesRecent News About These CompaniesLisata Therapeutics (NASDAQ:LSTA) Stock Price Up 4.3% - Here's WhyJune 11 at 2:21 AM | americanbankingnews.comLisata Therapeutics, Inc.: Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.June 10 at 11:20 AM | finanznachrichten.deLisata Therapeutics agrees to Kuva Labs buyout at $4 per shareJune 10 at 9:38 AM | proactiveinvestors.comLisata Therapeutics Announces Tender Offer from Kuva Acquisition Corp at $4.00 per Share Plus Contingent Value RightsJune 10 at 8:30 AM | quiverquant.comQLisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.June 10 at 8:00 AM | globenewswire.comKuva and Lisata Therapeutics Tender Offer UpdateJune 1, 2026 | tennessean.comTHC Wainwright & Co. downgrades Lisata Therapeutics (LSTA)May 16, 2026 | msn.comLisata Therapeutics Amends Kuva Labs Merger Agreement TimelineMay 9, 2026 | theglobeandmail.comHalper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their ShareholdersMay 4, 2026 | globenewswire.comLisata Therapeutics Delays Tender Offer Launch in MergerApril 3, 2026 | tipranks.comLeading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum CommunicationsMarch 26, 2026 | businesswire.comLisata Therapeutics shares up 20% as Kuva Labs acquisition advancesMarch 10, 2026 | finance.yahoo.comLisata Therapeutics to be acquired by Kuva LabsMarch 9, 2026 | proactiveinvestors.comShareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public ShareholdersMarch 9, 2026 | prnewswire.comLisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.March 6, 2026 | globenewswire.comLisata Extends Kuva Labs Acquisition Term Sheet TimelineFebruary 27, 2026 | tipranks.comLisata Therapeutics (LSTA) price target decreased by 26.92% to 9.69February 4, 2026 | msn.comLisata Therapeutics ends Qilu certepetide collaboration dealJanuary 27, 2026 | tipranks.comLisata regains China rights to pancreatic cancer drugJanuary 27, 2026 | proactiveinvestors.comLisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for CertepetideJanuary 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Rocket Lab Is Down 24% From Its 52-Week High—Pullback or Problem?By Ryan Hasson | June 4, 20262 Software Stocks Turning AI Fears Into Fundamental GainsBy Dan Schmidt | May 21, 2026MongoDB Is the Latest SaaS Apocalypse Victim to Say "Not Today"By Sam Quirke | June 3, 2026Allstate’s Comeback Is Turning Into a Profit MachineBy Peter Frank | June 8, 2026IMRN, ATHE, GRCE, and LSTA Company DescriptionsAlterity Therapeutics NASDAQ:ATHE$4.21 -201.29 (-97.95%) Closing price 04:00 PM EasternExtended Trading$4.30 +0.09 (+2.16%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Grace Therapeutics NASDAQ:GRCE$2.20 -0.10 (-4.35%) Closing price 04:00 PM EasternExtended Trading$2.25 +0.05 (+2.27%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.Immuron NASDAQ:IMRN$1.19 -0.05 (-4.03%) Closing price 04:00 PM EasternExtended Trading$1.18 -0.01 (-0.50%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.Lisata Therapeutics NASDAQ:LSTA$3.56 +0.08 (+2.30%) Closing price 04:00 PM EasternExtended Trading$3.56 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
